Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib maintenance in platinum-sensitive recurrent ovarian cancer previously treated with PARP inhibitors
ChiCTR2500108180Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of senaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
senaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500108180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108180.